XML 22 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Revenue Income Statement (Details) - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue $ 9,449.4 $ 9,107.9 $ 8,064.5
Billable expenses 1,478.4 1,132.8 996.5
Total revenue 10,927.8 10,240.7 9,061.0
OPERATING EXPENSES:      
Salaries and related expenses 6,258.3 5,975.4 5,345.0
Office and other direct expenses 1,346.4 1,279.6 1,367.9
Billable expense 1,478.4 1,132.8 996.5
Cost of services 9,083.1 8,387.8 7,709.4
Selling, General and Administrative Expense 87.1 122.3 58.8
Depreciation and amortization 274.0 283.8 290.6
Total operating expenses 9,546.6 8,804.5 8,472.6
Operating Income (Loss) 1,381.2 1,436.2 588.4
EXPENSES AND OTHER INCOME:      
Interest Expense (174.7) (173.1) (192.2)
Interest income 63.4 29.7 29.5
Other expense, net (1.0) (70.7) (64.4)
Total (expenses) and other income (112.3) (214.1) (227.1)
Income before income taxes 1,268.9 1,222.1 361.3
Provision for income taxes 318.4 251.8 8.0
Income of consolidated companies 950.5 970.3 353.3
Equity in net income of unconsolidated affiliates 5.6 2.5 0.9
NET INCOME 956.1 972.8 354.2
Net Income Attributable to Parent $ 938.0 $ 952.8 $ 351.1
Earnings per share, Basic $ 2.40 $ 2.42 $ 0.90
Earnings per share, Diluted $ 2.37 $ 2.39 $ 0.89
Weighted-average number of common shares outstanding, Basic 391.5 393.0 389.4
Weighted-average number of common shares outstanding, Diluted 395.1 398.4 393.2
MD&E      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue $ 4,111.5 $ 3,973.6 $ 3,451.2
Total revenue 4,196.7 4,061.7 3,520.4
IA&C      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 3,951.7 3,823.8 3,427.5
Total revenue 4,325.5 4,176.7 3,724.6
SC&E      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 1,386.2 1,310.5 1,185.8
Total revenue 2,405.6 2,002.3 1,816.0
United States      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 6,157.7 5,763.1 5,211.4
Total revenue 7,031.0 6,360.2 5,751.5
United States | MD&E      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 2,512.1 2,403.6 2,168.9
Total revenue 2,547.8 2,432.6 2,196.6
United States | IA&C      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 2,662.5 2,454.4 2,230.3
Total revenue 2,768.3 2,555.4 2,323.0
United States | SC&E      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 983.1 905.1 812.2
Total revenue 1,714.9 1,372.2 1,231.9
Total International      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 3,291.7 3,344.8 2,853.1
Total revenue 3,896.8 3,880.5 3,309.5
Total International | MD&E      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 1,599.4 1,570.0 1,282.3
Total revenue 1,648.9 1,629.1 1,323.8
Total International | IA&C      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 1,289.2 1,369.4 1,197.2
Total revenue 1,557.2 1,621.3 1,401.6
Total International | SC&E      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Net revenue 403.1 405.4 373.6
Total revenue $ 690.7 $ 630.1 $ 584.1